The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Olanzapine versus other atypical antipsychotics for schizophrenia
Open accessAbstract
BACKGROUND: In many countries of the industrialised world second generation ("atypical") antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examined how the efficacy and tolerability of olanzapine differs from that of other second generation antipsychotics. OBJECTIVES: To evaluate the effects of olanzapine compared to other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis. SEARCH STRATEGY: 1. Electronic searching We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO.2. Reference searching We inspected the reference of all identified studies for more trials.3. Personal contact We contacted the first author of each included study for missing information.4. Drug companies We contacted the manufacturers of all atypical antipsychotics included for additional data. SELECTION CRITERIA: We included all randomised trials that used at least single-blind (rater-blind) design, comparing oral olanzapine with oral forms of amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated weighted mean differences (WMD) again based on a random effects model. MAIN RESULTS: The review currently includes 50 studies and 9476 participants which provided data for six comparisons (olanzapine compared to amisulpride, aripiprazole, clozapine, quetiapine, risperidone or ziprasidone). The overall attrition from the included studies was considerable (49.2%) leaving the interpretation of results problematic.Olanzapine improved the general mental state (PANSS total score) more than aripiprazole (2 RCTs, n=794, WMD -4.96 CI -8.06 to -1.85), quetiapine (10 RCTs, n=1449, WMD -3.66 CI -5.39 to -1.93), risperidone (15 RCTs, n=2390, WMD -1.94 CI -3.31 to -0.58) and ziprasidone (4 RCTs, n=1291, WMD -8.32 CI -10.99 to -5.64), but not more than amisulpride or clozapine. This somewhat better efficacy was confirmed by fewer participants in the olanzapine groups leaving the studies early due to inefficacy of treatment compared to quetiapine (8 RCTs, n=1563, RR 0.56 CI 0.44 to 0.70, NNT 11 CI 6 to 50), risperidone (14 RCTs, n=2744, RR 0.78 CI 0.62 to 0.98, NNT 50 CI 17 to 100) and ziprasidone (5 RCTs, n=1937, RR 0.64 CI 0.51 to 0.79, NNT 17, CI 11 to 33).Fewer participants in the olanzapine group than in the quetiapine (2 RCTs, n=876, RR 0.56 CI 0.41 to 0.77, NNT 11 CI 7 to 25) and ziprasidone (2 RCTs, n=766, RR 0.65 CI 0.45 to 0.93, NNT 17 CI 9 to 100) treatment groups, but not in the clozapine group (1 RCT, n=980, RR 1.28 CI 1.02 to 1.61, NNH not estimable), had to be re-hospitalised in the trials.Except for clozapine, all comparators induced less weight gain than olanzapine (olanzapine compared to amisulpride: 3 RCTs, n=671, WMD 2.11kg CI 1.29kg to 2.94kg; aripiprazole: 1 RCT, n=90, WMD 5.60kg CI 2.15kg to 9.05kg; quetiapine: 7 RCTs, n=1173, WMD 2.68kg CI 1.10kg to 4.26kg; risperidone: 13 RCTs, n=2116, WMD 2.61kg CI 1.48kg to 3.74kg; ziprasidone: 5 RCTs, n=1659, WMD 3.82kg CI 2.96kg to 4.69kg). Associated problems such as glucose and cholesterol increase were usually also more frequent in the olanzapine group.Other differences in adverse effects were less well documented. Nevertheless, olanzapine may be associated with slightly more extrapyramidal side effects than quetiapine (use of antiparkinson medication (6 RCTs, n=1090, RR 2.05 CI 1.26 to 3.32, NNH 25 CI 14 to 100), but less than risperidone (use of antiparkinson medication 13 RCTs, n=2599, RR 0.78 CI 0.65 to 0.95, NNH 17 CI 9 to 100) and ziprasidone (use of antiparkinson medication 4 RCTs, n=1732, RR 0.70 CI 0.50 to 0.97, NNH not estimable). It may also increase prolactin somewhat more than aripiprazole, clozapine and quetiapine, but clearly less so than risperidone (6 RCTs, n=1291, WMD -22.84 CI -27.98 to -17.69). AUTHORS' CONCLUSIONS: Olanzapine may be a somewhat more efficacious drug than some other second generation antipsychotic drugs. This small superiority in efficacy needs to be weighed against a larger weight gain and associated metabolic problems than most other second generation antipsychotic drugs, except clozapine. These conclusions are tentative due to the large number of people leaving the studies early which possibly limits the validity of the findings. Further large, well-designed trials are necessary to establish the re
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
The world health report 2001 - Mental health: new understanding, new hope
Sayers, J. G. (2001) · Europe PMC (PubMed Central) · doi:10.1590/s0042-96862001001100014 · Cited by 3,123
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,701
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Scale for Assessment of Positive Symptoms (SAPS) 1984
Andreasen, N. C. (1995) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 2,423
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568 · cited 2×
“If both were missing we estimated SDs from p-values or used the average SD of the other studies (Furukawa 2006) Unit of analysis issues 1.”
BackgroundMethodRevising axis V for DSM-IV: a review of measures of social functioning
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1148 · Cited by 1,407
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,348
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
Self-citationUkoumunne, Gulliford, Chinn, Sterne, & Burney (1999) · Health Technology Assessment · doi:10.3310/hta3050 · Cited by 1,210
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Marwaha, S., & Johnson, S. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0762-4 · Cited by 922
Clinical implications of Brief Psychiatric Rating Scale scores
Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.4.366 · Cited by 896
Self-citation(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Marshall, M., Lockwood, A., Bradley, C., Adams, C., Joy, C., & Fenton, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.249 · Cited by 870 · cited 2×
“Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia ( Marshall 2000).”
BackgroundGulliford, M. C., Ukoumunne, O. C., & Chinn, S. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009904 · Cited by 852
Bland, J. M., & Kerry, S. M. (1997) · BMJ · doi:10.1136/bmj.315.7108.600 · Cited by 754
The unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Issues in the meta-analysis of cluster randomized trials
Donner, A., & Klar, N. (2002) · Statistics in Medicine · doi:10.1002/sim.1301 · Cited by 734
Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology
TANDON, R., KESHAVAN, M., & NASRALLAH, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.011 · Cited by 720
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].
Boissel, J., Cucherat, M., Li, W., Châtellier, G., Gueyffier, F., Buyse, M. E., Boutitie, F., Nony, P., Haugh, M., & Mignot, G. (1999) · PubMed · Cited by 533
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Carpenter, W. T., & Buchanan, R. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403103301006 · Cited by 510
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Self-citationPurdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 469
Lindenmayer, J.-P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.290 · Cited by 465
Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.185 · Cited by 450
Self-citationVolavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Heresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
Harrigan, E. P., Miceli, J. J., Anziano, R., Watsky, E., Reeves, K. R., Cutler, N. R., Sramek, J., Shiovitz, T., & Middle, M. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104913.75206.62 · Cited by 363
Krakowski, M. I., Czobor, P., Citrome, L., Bark, N., & Cooper, T. B. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.622 · Cited by 352
Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs
Naber, D., Moritz, S., Lambert, M., Rajonk, F., Holzbach, R., Mass, R., Andresen, B., Frank, P., Rüdiger, H., Reinhard, M., et al. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00166-3 · Cited by 348
Conley, R. R., & Mahmoud, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 334
Sikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B. B., & Lieberman, J. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300327 · Cited by 308
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306
Standardized remission criteria in schizophrenia
van Os, J., Burns, T., Cavallaro, R., Leucht, S., Peuskens, J., Helldin, L., Bernardo, M., Arango, C., Fleischhacker, W., Lachaux, B., et al. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00659.x · Cited by 285
Self-citationBasson, B. R., Kinon, B. J., Taylor, C. C., Szymanski, K. A., Gilmore, J. A., & Tollefson, G. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0404 · Cited by 279
Tsuang, M. T. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770260031002 · Cited by 252
Olanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia
Conley, R. R., Tamminga, C. A., Bartko, J. J., Richardson, C., Peszke, M., Lingle, J., Hegerty, J., Love, R., Gounaris, C., & Zaremba, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.914 · Cited by 245
McQuade, R. D., Stock, E. G., Marcus, R. N., Jody, D. N., Abou-Gharbia, N., Vanveggel, S., Archibald, D., & Carson, W. H. (2004) · PubMed · Cited by 244
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A., & Indran, S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001359.pub2 · Cited by 237
Self-citationDavid, S. R., Taylor, C. C., Kinon, B. J., & Breier, A. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80086-7 · Cited by 237
Lewis, S., Davies, L., Jones, P., Barnes, T., Murray, R., Kerwin, R., Taylor, D., Hayhurst, K., Markwick, A., Lloyd, H., et al. (2006) · Health Technology Assessment · doi:10.3310/hta10170 · Cited by 233
Aripiprazole for schizophrenia
El-Sayeh, H. G., & Morganti, C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004578.pub3 · Cited by 230
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225
Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Kafantaris, V., Correll, C. U., & Kane, J. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.043 · Cited by 223
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202
Volavka, J., Czobor, P., Cooper, T. B., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., & Lieberman, J. A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0109 · Cited by 201
Citrome, L., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., McEvoy, J., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.11.1510 · Cited by 200
Delorme, R., Bille, A., Betancur, C., Mathieu, F., Chabane, N., Mouren-Simeoni, M. C., & Leboyer, M. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-1 · Cited by 197
Volavka, J., Czobor, P., Nolan, K., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., & Lieberman, J. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117424.05703.29 · Cited by 190
De Roos, A. J. (2013) · Myelodysplastic Syndromes · doi:10.1007/978-3-642-36229-3_2 · Cited by 189
Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association
Czobor, P., Volavka, J., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00003 · Cited by 185
Serum Leptin and Triglyceride Levels in Patients on Treatment With Atypical Antipsychotics
Atmaca, M., Kuloglu, M., Tezcan, E., & Ustundag, B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0516 · Cited by 181
Álvarez-Jiménez, M., González-Blanch, C., Vázquez-Barquero, J. L., Pérez-Iglesias, R., Martínez-García, O., Pérez-Pardal, T., Ramírez-Bonilla, M. L., & Crespo-Facorro, B. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0812 · Cited by 180
Keefe, R. S. E., Young, C. A., Rock, S. L., Purdon, S. E., Gold, J. M., & Breier, A. F. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.038 · Cited by 173
Simpson, G. M., Glick, I. D., Weiden, P. J., Romano, S. J., & Siu, C. O. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1837 · Cited by 170
Wu, R., Zhao, J., Liu, Z., Zhai, J., Guo, X., Guo, W., & Tang, J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0384-5 · Cited by 170
Dropout rates in randomised antipsychotic drug trials
Wahlbeck, K., Tuunainen, A., Ahokas, A., & Leucht, S. (2001) · Psychopharmacology · doi:10.1007/s002130100711 · Cited by 167
Self-citationCrespo-Facorro, B., Pérez-Iglesias, R., Ramirez-Bonilla, M., Martínez-García, O., LLorca, J., & Vázquez-Barquero, J. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1004 · Cited by 159
Harvey, P. D., Green, M. F., McGurk, S. R., & Meltzer, H. Y. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1342-5 · Cited by 156
Breier, A. F., Berg, P. H., Thakore, J. H., Naber, D., Gattaz, W. F., Cavazzoni, P. A., Walker, D. J., Roychowdhury, S. M., & Kane, J. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1879 · Cited by 156
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147
Chrzanowski, W., Marcus, R. N., Torbeyns, A. F., Nyilas, M., & McQuade, R. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0564-3 · Cited by 146
The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine
Kern, R. S., Green, M. F., Cornblatt, B. A., Owen, J. R., McQuade, R. D., Carson, W. H., Ali, M. W., & Marcus, R. N. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0428-x · Cited by 145
Olanzapine and haloperidol in first episode psychosis: Two-year data
Green, A. I., Lieberman, J. A., Hamer, R. M., Glick, I. D., Gur, R. C., Kahn, R. S., McEvoy, J. P., Perkins, D. O., Rothschild, A. J., Sharma, T., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.021 · Cited by 134
Subjective well-being and quality of life under atypical antipsychotic treatment
Karow, A., & Naber, D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1052-z · Cited by 133
Dakhale, G. N., Khanzode, S. D., Khanzode, S. S., & Saoji, A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0117-1 · Cited by 131
Bourgeois, M. L., Swendsen, J. D., Young, F. K., AMADOR, X. F., Pini, S., Cassano, G. B., Lindenmayer, J., Hsu, C., Alphs, L. D., Meltzer, H. Y., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1494 · Cited by 131
Aripiprazole for schizophrenia: Systematic review
El-Sayeh, H. G. G., Morganti, C., & Adams, C. E. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.189.2.102 · Cited by 130
Czekalla, J., Beasley, C. M., Dellva, M. A., Berg, P. H., & Grundy, S. L. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0310 · Cited by 121
Robinson, D. G., Woerner, M. G., Napolitano, B. A., Patel, R. C., Sevy, S. M., Gunduz‐Bruce, H., Soto-Perello, J. M., Mendelowitz, A. J., Khadivi, A., Miller, R., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2096 · Cited by 120
Ascher‐Svanum, H., Zhu, B., Faries, D. E., Landbloom, R. P., Swartz, M. S., & Swanson, J. W. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-8 · Cited by 114
Quednow, B. B., Wagner, M., Westheide, J., Beckmann, K., Bliesener, N., Maier, W., & Kühn, K.-U. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.012 · Cited by 111
Citrome, L., Casey, D. E., Daniel, D. G., Wozniak, P., Kochan, L. D., & Tracy, K. A. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.3.290 · Cited by 111
The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
Fleischhacker, W. W., Keet, I. P. M., & Kahn, R. S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.06.004 · Cited by 110
Obsessive-Compulsive Symptoms During Treatment With Olanzapine and Risperidone
de Haan, L., Beuk, N., Hoogenboom, B., Dingemans, P. M. A. J., & LINSZEN, D. H. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0203 · Cited by 108
Potkin, S. G., Alphs, L. D., Hsu, C., Krishnan, K., Anand, R., Young, F. K., Meltzer, H. Y., & Green, A. I. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00178-1 · Cited by 106
Naber, D., Riedel, M. J., Klimke, A., Vorbach, E.-U., Lambert, M., Kühn, K. ‐., Bender, S., Bandelow, B., Lemmer, W., Moritz, S., et al. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00486.x · Cited by 102
Jeste, D. V., Barak, Y., Madhusoodanan, S., Grossman, F., & Gharabawi, G. M. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200311000-00008 · Cited by 102
Lecrubier, Y., Quintin, P., Bouhassira, M., Perrin, E., & Lancrenon, S. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00887.x · Cited by 95
Harvey, P. D., SIU, C. O., & Romano, S. J. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1652-2 · Cited by 93
Dossenbach, M. R. K., Arango-Dávila, C. A., Ibarra, H. S., Landa, E., Aguilar, J., Caro, O., Leadbetter, J., & Assunção, S. S. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0810 · Cited by 93
Beasley, C. M., Sutton, V. K., Hamilton, S. H., Walker, D. J., Dossenbach, M. R. K., Taylor, C. C., Alaka, K., Bykowski, D., & Tollefson, G. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095348.32154.ec · Cited by 91
Vaughan, K., McConaghy, N., Wolf, C., Myhr, C., & Black, T. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2000.00813.x · Cited by 91
Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis
Huber, T. J., Borsutzky, M., Schneider, U., & Emrich, H. M. (2004) · Acta Psychiatrica Scandinavica · doi:10.1046/j.1600-0447.2003.00251.x · Cited by 86
Double-Blind Study of Clozapine Dose Response in Chronic Schizophrenia
Simpson, G. M., Josiassen, R. C., Stanilla, J. K., de León, J., Nair, C., Abraham, G., Odom-White, A., & Turner, R. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1744 · Cited by 84
The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia.
Fleischhacker, W. W., Bergmann, K. J., Perovich, R., Pestreich, L. K., Borenstein, M., Lieberman, J. A., & Kane, J. M. (1989) · PubMed · Cited by 83
Risperidone versus olanzapine for schizophrenia
Jayaram, M., Hosalli, P., & Stroup, T. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005237.pub2 · Cited by 83
Six-Month, Blinded, Multicenter Continuation Study of Ziprasidone Versus Olanzapine in Schizophrenia
Simpson, G. M., Weiden, P. J., Pigott, T., Murray, S., SIU, C. O., & Romano, S. J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1535 · Cited by 83
Kinon, B. J., Lipkovich, I. A., Edwards, S. B., Adams, D. H., Ascher‐Svanum, H., & Siris, S. G. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000204137.82298.06 · Cited by 83
Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia
Lindenmayer, J., Czobor, P., Volavka, J., Lieberman, J. A., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., & Chakos, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0416 · Cited by 81
Mortimer, A. M., Martin, S. D., Löo, H., & Peuskens, J. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200403000-00002 · Cited by 81
Wagner, M., Quednow, B. B., Westheide, J., Schlaepfer, T. E., Maier, W., & Kühn, K.-U. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300626 · Cited by 80
Gureje, O., Miles, W., Keks, N. A., Grainger, D. L., Lambert, T., McGrath, J. J., Tran, P., Catts, S. V., Fraser, A., Hustig, H., et al. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00226-8 · Cited by 77
Weickert, T. W., Goldberg, T. E., Marenco, S., Bigelow, L. B., Egan, M. F., & Weinberger, D. R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300216 · Cited by 76
Nolan, K. A., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., & Lieberman, J. A. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.04.010 · Cited by 76
Harvey, P. D., Napolitano, J. A., Mao, L., & Gharabawi, G. M. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.929 · Cited by 75
Wynn, J. K., Green, M. F., Sprock, J., Light, G. A., Widmark, C., Reist, C., Erhart, S. M., Marder, S. R., Mintz, J., & BRAFF, D. L. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.039 · Cited by 74
Purdon, S. E., Woodward, N. D., Lindborg, S. R., & Stip, É. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1505-z · Cited by 73
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia
Sharma, T., Hughes, C., Soni, W., & Kumari, V. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1506-y · Cited by 73
Kinon, B. J., Noordsy, D. L., Liu‐Seifert, H., Gulliver, A. H., Ascher‐Svanum, H., & Kollack‐Walker, S. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000236658.16286.25 · Cited by 73
Bitter, I., Basson, B. R., & Dossenbach, M. R. K. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200501000-00004 · Cited by 72
Sowell, M. O., Mukhopadhyay, N. D., Cavazzoni, P. A., Carlson, C. D., Mudaliar, S. R. D., Chinnapongse, S., Ray, A. J., Davis, T., Breier, A. F., Henry, R. R., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021884 · Cited by 71
The treatment of psychotic depression.
Coryell, W. H. (1998) · PubMed · Cited by 69
Treatment programme and long‐term outcome in chronic schizophrenia
Kane, J. M. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05309.x · Cited by 64
Olanzapine: a novel atypical neuroleptic agent
Reus, V. I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)22018-0 · Cited by 62
Bender, S., Dittmann-Balçar, A., Schall, U., Wolstein, J. R., Klimke, A., Riedel, M. J., Vorbach, E.-U., Kühn, K.-U., Lambert, M., Dittmann, R., et al. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005924 · Cited by 61
Kinon, B. J., Stauffer, V. L., Kollack‐Walker, S., Chen, L., & Sniadecki, J. L. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818aaf6c · Cited by 61
Álvarez, E., Ciudad, A., Olivares, J. M., Bousoño, M., & Gómez, J. C. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222513.63767.de · Cited by 61
Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia
Mori, K., Nagao, M., Yamashita, H., Morinobu, S., & Yamawaki, S. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.01.019 · Cited by 59
Tunis, S. L., Faries, D. E., Nyhuis, A. W., Kinon, B. J., Ascher‐Svanum, H., & Aquila, R. (2005) · Value in Health · doi:10.1111/j.1524-4733.2006.00083.x · Cited by 59
Goldberg, T. E., Dodge, M. R., Aloia, M. S., Egan, M. F., & Weinberger, D. R. (2000) · Psychological Medicine · doi:10.1017/s0033291799002639 · Cited by 58
Voruganti, L. P., AWAD, A., PARKER, G., Forrest, C. B., USMANI, Y., Fernando, M. L. D., & SENTHILAL, S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.002 · Cited by 57
Riedel, M. J., Müller, N., Spellmann, I., Engel, R. R., Musil, R., Valdevit, R., Dehning, S., Douhet, A., Cerovecki, A., Strassnig, M., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0748-9 · Cited by 56
Riedel, M. J., Spellmann, I., Strassnig, M., Douhet, A., Dehning, S., Opgen-Rhein, M., Valdevit, R., Engel, R. R., Kleindienst, N., Müller, N., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0739-x · Cited by 53
Kelly, D. L., Conley, R. R., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003) · Annals of Clinical Psychiatry · doi:10.1023/b:acli.0000008171.90644.f8 · Cited by 53
Glick, I. D., Zaninelli, R., Hsu, C., Young, F. K., Weiss, L., Günay, İ., & Kumar, V. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0513 · Cited by 52
Glick, I. D., & Berg, P. H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200203000-00004 · Cited by 51
Moresco, R. M., Cavallaro, R., Messa, C., Bravi, D., Gobbo, C. L., Galli, L., Lucignani, G., Colombo, C., Rizzo, G., Velonà, I., et al. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800306 · Cited by 46
A crossover study on lipid and weight changes associated with olanzapine and risperidone
Su, K., Wu, P.-L., & Pariante, C. M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0205-2 · Cited by 44
Alphs, L. D., Anand, R., Islam, M., Meltzer, H. Y., Kane, J. M., Krishnan, R. R., Green, A. I., Potkin, S. G., Chouinard, G., Lindenmayer, J., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007102 · Cited by 43
Moritz, S., Woodward, T. S., Krausz, M. R., & Naber, D. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200201000-00007 · Cited by 38
WANG, X., Savage, R. J., Borisov, A. S., ROSENBERG, J., Woolwine, B. J., TUCKER, M., May, R., FELDMAN, J., Nemeroff, C. B., & MILLER, A. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.03.008 · Cited by 37
Feldman, P. D., Kaiser, C. J., Kennedy, J. S., Sutton, V. K., Trân, P. V., Tollefson, G. D., Zhang, F., & Breier, A. F. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0904 · Cited by 35
Vanelle, J., & Douki, S. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2006.09.003 · Cited by 35
van Bruggen, J., TIJSSEN, J., Dingemans, P., Gersons, B. P. R., & Linszen, D. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200311000-00005 · Cited by 34
Aktuelle Bewertung neuer/atypischer Neuroleptika
Møller, H. J. (2000) · Der Nervenarzt · doi:10.1007/s001150050567 · Cited by 32
Yamashita, H., Mori, K., Nagao, M., Okamoto, Y., Morinobu, S., & Yamawaki, S. (2005) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200505000-00006 · Cited by 30
Deberdt, W. G., Lipkovich, I., Heinloth, A. N., Liu, L., Kollack‐Walker, S., Edwards, S., Hoffmann, V. P., & Hardy, T. A. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3153 · Cited by 29
Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration
Karow, A., & Naber, D. (2002) · Current Opinion in Psychiatry · doi:10.1097/00001504-200201000-00006 · Cited by 28
Computed tomographic evaluation of patients with tardive dyskinesia
Hoffman, W. F., & Casey, D. E. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90048-v · Cited by 26
Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients
Briken, P., Nika, E., Moritz, S., Haasen, C., Perro, C., Yagdiran, O., Naber, D., & Krausz, M. R. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00322-x · Cited by 25
MALLA, A. K., Norman, R. M. G., Scholten, D. J., Townsend, L. A., Manchanda, R., Takhar, J., & Haricharan, R. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.07.008 · Cited by 25
Apiquián, R., Fresán, A., Herrera, K., Ulloa, R. E., Lóyzaga, C., de la Fuente‐Sandoval, C., Gutiérrez, D., & Nicolini, H. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003742 · Cited by 24
Buckley, P. F., Krowinski, A. C., Miller, D. D., Friedman, L., Eaton, Y., & Tronetti, M. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00084-5 · Cited by 21
Lee, C., Wu, K.-H., Habil, H., Dyachkova, Y., & Lee, P. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01820.x · Cited by 17
Health of the Nation Outcome Scale (HoNOS). Presentazione
Ruggeri, M. (2001) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00005327 · Cited by 14
Wolf, K., Maß, R., Kiefer, F., Eckert, K., Stritzky, A. V., Haasen, C., Wiedemann, K., & Naber, D. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000165739.55142.23 · Cited by 13
Wortis, J. (1972) · PubMed · Cited by 10
▼Olanzapine, ▼sertindole and schizophrenia
(1997) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.1997.351181 · Cited by 8
Ray, S., Corey‐Lisle, P. K., Cislo, P. K., L'Italien, G. J., & Weiden, P. J. (2004) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(04)80327-4 · Cited by 7
Blonde, L., Ray, S. K., Corey‐Lisle, P. K., Cislo, R. R., & L'Italien, G. J. (2004) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(04)80317-1 · Cited by 5
Vanelle, J., & Douki, S. (2004) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(04)80338-9 · Cited by 2
Almond, S., O’Donnell, O., & McKendrick, J. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)80350-2 · Cited by 2
Cited by
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq042 · Cited by 272
Self-citationTrends in the utilisation of psychotropic medications in Australia from 2000 to 2011
Stephenson, C. P., Karanges, E., & McGregor, I. S. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412466595 · Cited by 217
“While some large-scale studies suggest that olanzapine may be a more efficacious first-line treatment for psychosis than other atypicals, the clinical significance of these benefits has been questioned (Komossa et al., 2010).”
BackgroundInfluential
Metadata
- Authors
- Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-03-17
- Volume
- 2013
- Issue
- 5
- Pages
- CD006654-CD006654
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2147522149
- Cited by
- 365
- References
- 164
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.